Kasper B Kristensen1, Daniel P Henriksen2,3, Jesper Hallas2, Anton Pottegård2, Lars C Lund2. 1. Clinical Pharmacology and Pharmacy, Department of Public Health, University of Southern Denmark, Odense, Denmark. kaskristensen@health.sdu.dk. 2. Clinical Pharmacology and Pharmacy, Department of Public Health, University of Southern Denmark, Odense, Denmark. 3. Department of Clinical Biochemistry and Pharmacology, Odense University Hospital, Odense, Denmark.
Abstract
AIMS/HYPOTHESIS: Sodium-glucose cotransporter 2 inhibitors (SGLT2Is) may reduce nephrolithiasis risk by increasing urine flow. We aimed to investigate whether initiation of SGLT2I was associated with reduced nephrolithiasis risk. METHODS: We conducted an active-comparator new-user cohort study using the Danish health registries in the period 11 November 2012 to 31 December 2018. Individuals aged ≥40 years initiating SGLT2Is or glucagon-like peptide-1 receptor agonists (GLP1 RAs) were followed from treatment initiation until an inpatient or outpatient diagnosis of nephrolithiasis, death, emigration or end of study. New users of SGLT2Is were matched 1:1 on propensity scores to new users of GLP1 RAs. In supplementary analyses, risk of recurrent nephrolithiasis was assessed in individuals with a history of nephrolithiasis before treatment initiation. RESULTS: We identified 24,290 and 19,576 eligible users of SGLT2Is and GLP1 RAs, respectively. After matching, 12,325 patient pairs remained. The median age was 61 years and median follow-up was 2.0 years. The nephrolithiasis rate was 2.0 per 1000 person-years in SGLT2I initiators compared with 4.0 per 1000 person-years in GLP1 RA initiators, with a rate difference of -1.9 per 1000 person-years (95% CI -2.8, -1.0) and an HR of 0.51 (95% CI 0.37, 0.71). For recurrent nephrolithiasis (n = 731 patient pairs), the rate difference was -17 per 1000 person-years (95% CI -33, -1.5) and the HR was 0.68 (95% CI 0.48, 0.97). CONCLUSIONS/ INTERPRETATION: Initiation of treatment with SGLT2Is was associated with a clinically significant reduced risk of incident and recurrent nephrolithiasis.
AIMS/HYPOTHESIS: Sodium-glucose cotransporter 2 inhibitors (SGLT2Is) may reduce nephrolithiasis risk by increasing urine flow. We aimed to investigate whether initiation of SGLT2I was associated with reduced nephrolithiasis risk. METHODS: We conducted an active-comparator new-user cohort study using the Danish health registries in the period 11 November 2012 to 31 December 2018. Individuals aged ≥40 years initiating SGLT2Is or glucagon-like peptide-1 receptor agonists (GLP1 RAs) were followed from treatment initiation until an inpatient or outpatient diagnosis of nephrolithiasis, death, emigration or end of study. New users of SGLT2Is were matched 1:1 on propensity scores to new users of GLP1 RAs. In supplementary analyses, risk of recurrent nephrolithiasis was assessed in individuals with a history of nephrolithiasis before treatment initiation. RESULTS: We identified 24,290 and 19,576 eligible users of SGLT2Is and GLP1 RAs, respectively. After matching, 12,325 patient pairs remained. The median age was 61 years and median follow-up was 2.0 years. The nephrolithiasis rate was 2.0 per 1000 person-years in SGLT2I initiators compared with 4.0 per 1000 person-years in GLP1 RA initiators, with a rate difference of -1.9 per 1000 person-years (95% CI -2.8, -1.0) and an HR of 0.51 (95% CI 0.37, 0.71). For recurrent nephrolithiasis (n = 731 patient pairs), the rate difference was -17 per 1000 person-years (95% CI -33, -1.5) and the HR was 0.68 (95% CI 0.48, 0.97). CONCLUSIONS/ INTERPRETATION: Initiation of treatment with SGLT2Is was associated with a clinically significant reduced risk of incident and recurrent nephrolithiasis.
Authors: Elisabetta Patorno; Ajinkya Pawar; Jessica M Franklin; Mehdi Najafzadeh; Anouk Déruaz-Luyet; Kimberly G Brodovicz; Steven Sambevski; Lily G Bessette; Adrian J Santiago Ortiz; Martin Kulldorff; Sebastian Schneeweiss Journal: Circulation Date: 2019-04-08 Impact factor: 29.690
Authors: Sebastian Schneeweiss; Jeremy A Rassen; Robert J Glynn; Jerry Avorn; Helen Mogun; M Alan Brookhart Journal: Epidemiology Date: 2009-07 Impact factor: 4.822
Authors: Morten Schmidt; Sigrun Alba Johannesdottir Schmidt; Jakob Lynge Sandegaard; Vera Ehrenstein; Lars Pedersen; Henrik Toft Sørensen Journal: Clin Epidemiol Date: 2015-11-17 Impact factor: 4.790
Authors: Daniel C Rosen; Jacob N Bamberger; Elie Kaplan-Marans; Ishan Paranjpe; Arjun Kapoor; Blair Gallante; Daniel J Atashsokhan; Anna M Zampini; Johnathan A Khusid; William M Atallah; Mantu Gupta Journal: Can Urol Assoc J Date: 2022-02 Impact factor: 1.862
Authors: Priyadarshini Balasubramanian; Christoph Wanner; João Pedro Ferreira; Anne Pernille Ofstad; Amelie Elsaesser; Bernard Zinman; Silvio E Inzucchi Journal: J Clin Endocrinol Metab Date: 2022-06-16 Impact factor: 6.134